Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies.

ABSTRACT:

Background

Transarterial therapy, including transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), has long been a cornerstone in the management of unresectable hepatocellular carcinoma (uHCC). In parallel, the emergence of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein 1 (PD-1) antibodies has reshaped the systemic treatment landscape. Recently, the combination of transarterial therapy with TKIs and anti-PD-1 antibodies has shown promising efficacy in treating uHCC, but lacks a standardized prognostic model.

Methods

We retrospectively included 243 patients with uHCC treated with transarterial therapy plus TKIs and anti-PD-1 antibodies, divided into training (n = 169) and validation (n = 74) cohorts. Within the trai

SUBMITTER: Yuan T 

PROVIDER: S-EPMC12817772 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature